Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609974 | 0.91 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL320827 | 0.83 | ALDH1A1 (0.40) | — | |
| SCHEMBL320661 | 0.82 | — | — | |
| SCHEMBL2744125 | 0.80 | ALDH1A1 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29728731 | 0.80 | ALDH1A1 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2035783 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL320409 | 0.78 | — | — | |
| SCHEMBL2991210 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL30584565 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL609442 | 0.74 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485314-A1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary cell | Mitsubishi Chemical Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8178246-B2 | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary cell, and carbonate compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | CHRNB2 2491/4885CHRNA4 2042/4885CHRNB4 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.